Use of Oral Cholera Vaccine in Haiti: A Rural Demonstration Project by Ivers, Louise C. et al.




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ivers, L. C., J. E. Teng, J. Lascher, M. Raymond, J. Weigel, N.
Victor, J. G. Jerome, et al. 2013. “Use of Oral Cholera Vaccine in
Haiti: A Rural Demonstration Project.” The American Journal of




Accessed February 19, 2015 2:44:25 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878978
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Am. J. Trop. Med. Hyg., 89(4), 2013, pp. 617–624
doi:10.4269/ajtmh.13-0183
Copyright © 2013 by The American Society of Tropical Medicine and Hygiene
Use of Oral Cholera Vaccine in Haiti: A Rural Demonstration Project
Louise C. Ivers,* Jessica E. Teng,* Jonathan Lascher, Max Raymond, Jonathan Weigel, Nadia Victor,
J. Gregory Jerome, Isabelle J. Hilaire, Charles P. Almazor, Ralph Ternier, Jean Cadet,
Jeannot Francois, Florence D. Guillaume, and Paul E. Farmer
Division of Global Health Equity, Brigham and Women’s Hospital, Boston, Massachusetts; Partners In Health, Boston, Massachusetts;
Zanmi Lasante, St. Marc, Haiti; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts;
Ministry of Health and Population, Port-au-Prince, Haiti
Abstract. A cholera epidemic has claimed the lives of more than 8,000 Haitians and sickened 650,000 since the
outbreak began in October 2010. Early intervention in the epidemic focused on case-finding, treatment, and water and
sanitation interventions for prevention of transmission. Use of oral cholera vaccine (OCV) as part of a complementary
set of control activities was considered but initially rejected by policymakers. In December 2011, the Minister of Health
of Haiti called for a demonstration of the acceptability and feasibility of the use of OCV in urban and rural Haiti. This
paper describes the collaborative activity that offered OCV to one region of the Artibonite Department of rural Haiti
in addition to other ongoing treatment and control measures. Despite logistics and cold chain challenges, 45,417 persons
were successfully vaccinated with OCV in the region, and 90.8% of these persons completed their second dose.
BACKGROUND
Haiti is fighting the world’s largest cholera epidemic in
50 years. Since Vibrio cholerae was first detected in October
2010, 651,339 cases and 8,053 deaths have been reported by
the Haitian Ministry of Health (MOH).1 According to the
Pan-American Health Organization, some 1,500 new cases
have been reported each week in 2013.2 The extensive initial
local and international response to the cholera epidemic
in Haiti largely accorded with World Health Organization
(WHO) protocol: case-finding and rapid treatment by rehy-
dration, clean water and sanitation efforts, public health
messaging, and national surveillance.3 Oral cholera vaccine
(OCV), however, remained unavailable in Haiti until 2012.
In the first months of the epidemic, influential external policy
advisors, a high profile international non-governmental orga-
nization, and certain academics voiced concerns that intro-
ducing vaccine might trigger further social instability at a
time when election-year social frictions were already high
and vaccine availability was limited.4,5 Others worried that
vaccination would pull resources from other disease-control
priorities.6 Still, some argued that vaccination could be inte-
grated with other prevention and treatment activities and
therefore strengthen the overall response.7,8
Two types of OCV are currently available: WC-rBS
(marketed as DukoralÒ; Crucell, Leiden, The Netherlands)
and BivWC (marketed as ShancholÒ; Shantha Biotechnics,
Hyderabad, India). Neither vaccine is a panacea, but they
have proven safe and effective in diverse settings, largely
in endemic cholera regions.9 Both vaccines require use of cold
chain and must be given in two doses, 1–6 weeks apart.
In recent years, re-analysis of data from clinical trials demon-
strated that both vaccines confer considerable herd immunity
and interest in their use has increased.10 In 2010, WHO
revised guidelines on the use of OCV and included a recom-
mendation that in epidemic settings, reactive vaccination be
considered as an additional control measure in conjunction
with other prevention and control strategies.11
In December 2011, the MOH of Haiti requested that dem-
onstration projects be conducted in rural and urban Haiti to
establish the acceptability and feasibility of using OCV as part
of a comprehensive cholera control strategy for the country.
Partners In Health (PIH) and Le Groupe Haı¨tien d’Etude du
SarcomedeKaposietdesInfectionsOpportunistes(GHESKIO),
both non-governmental healthcare organizations with long-
time experience in Haiti, were early proponents of the inclu-
sion of OCV in control efforts and were thus well positioned
to respond rapidly to the Minister’s request for technical and
implementing partners. By that time, 523,904 Haitians had
been sickened by cholera and 7,018 had died.12 Some 300 cases
were being seen each week in the Artibonite and Central
Departments where PIH supports 11 public health facilities,
including cholera treatment and prevention activities.13
This report describes the use of OCV in a rural vaccination
campaign undertaken by PIH as an implementing partner of
the MOH. Our objective was to use available vaccine to pro-
vide protection to target recipients in rural Haiti before the
onset of the annual rainy season three months later. In doing
so, we aimed to demonstrate the acceptability and feasibility
of such a campaign, despite the challenges of delivering
healthcare in rural Haiti that were further heightened by the
ongoing epidemic.
PROCEDURES
Timeline. Long lead-time items for the project included
procurement and shipment of the vaccine and cold chain
inputs. In part because months of lack of consensus among
policymakers had resulted in public uncertainty, and in part
because the vaccine had only recently been pre-qualified by
WHO, concern arose from a national bioethics committee
that the vaccination project was experimental and the start
date was delayed while the appropriate ethics review took
place. Once the committee had reviewed revised documents
and understood that the project was a public health endeavor,
they approved the project to advance without concern. This
resulted in a six-week delay that impacted the strategy that
was used (see below) and also meant that the campaign began
at the start of the rainy season.
Project area. The campaign aimed to provide vaccination
access to a rural community in the Artibonite Department
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of Haiti. The project team chose to target an area called
Bocozel (Figure 1). After a census was performed, the number
of inhabitants of Bocozel was fewer than originally anticipated,
so a neighboring community (Grand Saline) was included in
the campaign to reach the objective of vaccinating 50,000 per-
sons. Although a number of alternate targeting strategies
might have been invoked, we elected to conduct the campaign
in this region of Haiti for a number of reasons: its rural isolated
nature with poor road infrastructure making access to health
services difficult; the close interaction of its inhabitants with
the Artibonite River (the source of the cholera epidemic); its
low-lying topography resulting in salination of water boreholes
and frequent flooding; and its lack of access to potable water
and the lack of a clear plan by the regional water authority for
investment in improved water access over the next five years.
In short, these were the characteristics of precisely those places
hardest-hit by epidemic cholera in Haiti.
Bocozel and Grand Saline are rural regions of Haiti near
the town of St. Marc and home to the largest rice-growing
region of Haiti. Vast plains of rice are irrigated by branches
of the Artibonite River and those areas not receiving such
irrigation are dry and desert-like. The inhabitants’ economic
situation is precarious; they live in shanty homes and have
poor dietary diversity, few potable water sources, and poor
access to sanitation. On most economic measures, their situa-
tion is worse than the nationwide average; 78% of persons
earning less than $2 a day.14 Small health centers provide
some primary care to people in the region but any complex
health problems must be addressed in the town of St. Marc,
a minimum of two hours away on foot. This region of Haiti
had been affected early by the cholera epidemic and an attack
rate two years into the epidemic was estimated at 5.1–7.5%.15
Stakeholder engagement and communications. Leading up
to the vaccination campaign, we undertook a series of key
stakeholder meetings and focus groups to better understand
how cholera vaccination might fit into the community context
and to support the generation of communications materials.
Stakeholder interviews were conducted with local public
health practitioners, the district health office, and leaders of
non-governmental organizations with activity in target areas.
We also held eight community meetings with local authorities,
religious leaders, school directors and teachers, traditional
healers, and birth attendants and an additional five focus
groups with 55 community residents. These meetings demon-
strated that although there was initially a lack of knowledge
about OCV, most stakeholders and potential beneficiaries
were eager to have access to this tool to prevent cholera,
in addition to improvements in clean water and sanitation
access. We also gathered information from these meetings
that was useful in the development of a communications cam-
paign. Ten key messages around cholera vaccination and
cholera prevention were generated and shared during the
campaign via radio shows, sound trucks (local vehicles with
megaphones), T-shirts, posters, and local television. At the
start of the campaign, the director general of the MOH spoke
on the radio about OCV.
Staff structure. The project team was comprised of staff
from PIH, as well as MOH representatives from the National
Vaccine Program and the local health coordination office.
Forty teams of four persons each were engaged in the delivery
Figure 1. Fixed vaccination posts and cold chain staging points in an oral cholera vaccination campaign in the communes of Bocozel and
Grand Saline, Haiti, 2012.
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of vaccine doses to the target population. Each team had
a medical records registrar, two vaccinators, and a crier. The
crier was from the locality being vaccinated that day, guiding
teams and alerting communities to the day’s activities usu-
ally by using a megaphone. Twenty supervisors led these
40 teams. No existing training manuals were (to our knowl-
edge) available on the use of OCV, so our PIH training
department in Haiti created a community health worker
training module and staff was trained over the course of two
and a half days.16
Logistics and cold chain. We chose between the two avail-
able vaccine brands based on cost and ease of use in the field.
On December 9, 2011, PIH executed an order for all 200,000
available doses of BivWC at a pre-negotiated price of $1.85
per dose. On March 1, 2012, 168 shippers carrying 200,000
doses of oral cholera vaccine arrived to Port-au-Prince by air
from India at 8:00 AM.
To ensure cold chain during the five-day transit between India
and Haiti, ice packs and 10-day electronic temperature moni-
toring devices (Q-tagÒ; Berlinger, Ganterschwil, Switzerland)
were included in each shipper. The shipment was cleared
through Haitian customs the same morning and awaiting trucks
transported half of the doses directly to St. Marc for use in the
rural component of the project, arriving by 2:00 PM the same
day. The remaining 100,000 doses were trucked to a warehouse
in Port-au-Prince for use in the urban campaign.
Because capacity for cold chain is limited in the rural iso-
lated part of Haiti in which we work, we devised a series
of steps to reinforce this capacity (Figure 1). In St. Marc,
vaccine was transferred from shippers to a 20-foot refrigerated
container where pre-arranged plastic shelving was used to
store the boxes, each containing 10 vials, for a total volume
of 6.31m3. From that time until the end of the campaign, the
temperature of the cold container was monitored twice a day.
Boxes remained wrapped until the day of use. Individual vials
were only handled when vaccinators administered the vaccine.
Every evening, 4,000–7,000 doses were transferred from the
cold container to refrigerated storage in a dispatching ware-
house for use the next day. Each morning, supervisors loaded
vaccines, ice packs, and a thermometer into cold boxes for
further transport to one of four health centers in Bocozel that
served as final staging areas. Here, vaccination teams met
supervisors, filled vacuum flask carriers with vaccines and
cold packs, and dispersed to their posts. A random selection
of flasks was equipped with thermometers, and teams
recorded temperatures throughout the vaccination day. Cold
chain was thus maintained up to the time of vaccination. At the
end of each day, unused vaccine was returned to refrigerated
storage at the dispatch warehouse and prioritized for use the
next day. Empty, used vials were stored in plastic bags with no
other waste and incinerated under the supervision of the ware-
house manager per the manufacturer’s recommendation.
Use of handheld technology. Data were collected by using
Samsung Galaxy version 7.0 Plus tablets running on an
Android operating system (Samsung, Seoul, South Korea) and
stored on a web-hosted database. The data collection software
used was Majella InsightÒ (Majella Global Technologies,
Portland, ME). Because of cost concerns, data collected in the
field were initially stored offline on the device and were later
uploaded to our cloud database at the project office via local
internet connection every evening. Because literacy levels are
low in the target area and past experience had shown that
personal identification cards are often unavailable, we required
a robust method to identify vaccine recipients so as to docu-
ment receipt of their second vaccine dose. We pre-printed
vaccine cards with unique numeric barcodes, thus assigning
each card a unique identification number. Using the tablet
computer’s built-in camera function, we scanned barcodes at
the time of vaccination, registered the vaccinee in the database
at which point the date, dose, and batch number were
recorded. If barcodes did not successfully scan, or if vaccination
cards were lost or missing, data were entered manually into the
tablet database at the point of vaccination.
Census. A census was performed in Bocozel before vacci-
nation began. During the census, field teams moved from
door-to-door across localities and collected information about
the household from the household head or another adult.
Each house was assigned a unique number. If no adult was
present, the house was noted and the team returned on a
subsequent day. Households were informed about cholera
vaccination and general cholera prevention techniques were
shared including water, sanitation, and hygiene messages.
Residents who were eligible and expressed interest in vacci-
nation were pre-registered and received a vaccine card with a
unique barcode. Household members that were not present
could be pre-registered by the responding adult and in this
case vaccine cards were left with the household representative.
Every tenth household was invited to participate in a short
survey of knowledge and attitudes regarding cholera and also
practices relevant to water-borne disease. When persons par-
ticipated in the survey, it was conducted before team members
shared information about the vaccine or other cholera preven-
tion measures.
Vaccination strategy. Vaccination occurred in two distinct
phases that targeted children less than 10 years of age sepa-
rately from other recipients. This phase was a necessary
adjustment to project plans because the six-week delay in the
timeline resulted in the OCV campaign schedule overlapping
with a national oral polio vaccination (OPV) campaign. We
received a manufacturer’s letter advising that OPV should be
avoided within 14 days of OCV administration. The first
phase therefore occurred in Bocozel during April 15–May 24,
2012 and excluded children less than 10 years of age. The
second phase targeted children less than 10 years of age, as well
as any remaining eligible persons of all ages and occurred
during May 27–June 19, 2012. Because the total census popula-
tion in Bocozel was smaller than first expected, the campaign
was expanded geographically in phase 2 to the neighboring
community of Grand Saline.
Initial vaccinations were performed at fixed or rally posts
in locations pre-determined by the communities and project
team. These posts were usually the same locations that MOH
officials use for childhood vaccination campaigns. Each eve-
ning, a daily report was generated from data collected in the
field. It included information about vaccinations performed
that day grouped by team and by locality, as well as the
cumulative total number of vaccinations. A combination
of these data, pre-registration data and field team feedback
were used to inform the next day’s field strategy. When this
nightly review of the data suggested that attendance at fixed
posts had slowed, teams moved to mobile posts. Mobile posts
were comprised of the same vaccination team but the location
was flexible, targeted to areas with low turn out to date.
Teams sometimes completed multiple mobile posts in one
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day, moving on to the next position when attendance slowed.
A final phase of vaccination occurred by using a door-to-door
approach. We generated lists of persons who had pre-registered
for the vaccine but who had not yet been vaccinated, along with
their addresses. Teams moved door-to-door to offer vaccina-
tion to those houses. This whole approach was repeated after
14 days for the administration of the second vaccine dose.
At all times during the campaign, vaccination remained vol-
untary. Children less than one year of age and pregnant women
were not eligible for vaccination. Pregnant women were asked
to self-identify for exclusion at each stage of the campaign.
If potential recipients presented requesting a first dose of vac-
cination out of cycle with the rest of the cohort, we did not
offer vaccination unless the timing ensured that a second dose
could be received in the project timeframe. In addition to
vaccine-specific information, teams shared water and sanita-
tion and hygiene messages during their interactions with com-
munity members because the objective of the project was to be
part of a comprehensive control effort rather than to supplant
one component with another.
Monitoring. Persons were observed for side effects at the
vaccination post for 30 minutes after receipt of the vaccine,
and community health workers performed passive follow-up
in the communities for side effects that might have occurred
later. Trained community nurses made home visits to review
persons reporting side effects. These side effects were desig-
nated as mild (no interference with daily activities), moderate
(some interference with daily activities), or severe (signifi-
cant, prevented daily activity).
In September 2012, three months after the vaccination cam-
paign, a follow-up survey was conducted in Bocozel as part
of routine program evaluation. Six hundred households were
randomly selected from the census data and information was
collected from respondents on vaccine coverage, as well as on
knowledge and attitudes about cholera. No personally iden-
tifiable information was gathered during this survey. Institu-
tional review board approval was obtained from Partners
Institutional Review Board (Boston, MA) for secondary anal-
ysis of the data collected during this survey.
RESULTS
Uptake.A total of 45,417 persons received at least one dose
of OCV. Of these persons, 90.8% were confirmed to have
received a second dose. Daily and cumulative vaccination
counts across all phases and doses and the strategy used dur-
ing each component are shown in Figure 2. Uptake of vaccine
and completion of second dose by location, sex, and age group
are shown in Table 1.
Coverage. We measured community coverage in Bocozel
in two ways. The first estimate used census data as the denom-
inator and included in the numerator only those recipients
of OCV that were confirmed to have been registered in that
community (i.e., their domicile was registered by the census).
Using these data, we found that community coverage was
76.7%. On vaccination days, some persons identified their
domicile to be in a certain community, but they could not be
found in the database. At the vaccine post, we had no way to
prove or disprove a person’s domicile. Thus, we also calcu-
lated coverage rates, including these self-reporting persons,
whereby they were added to the numerator and denominator.
Using this more inclusive method, we found that community
coverage in Bocozel was 79.2%.
We further measured community coverage by asking about
receipt of OCV during the post-campaign household survey.
A total of 480 (92.7%) of 518 respondents reported that they
had been vaccinated against cholera, of which 419 (87.3%)
of 480 produced a vaccination card as confirmation. Among
the 37 respondents reporting that they were not vaccinated,
18 (3.5%) reported not being present at the time of vaccina-
tion, 14 (2.7%) reported being ineligible at the time of vacci-
nation, 3 (< 1%) did not want the vaccine, 2 (< 0.5%) reported
other reasons; 1 person declined to respond. Because we did
not perform a census or pre-registration phase in Grand
Saline, we estimated community coverage, determined by using
2009 government demographic information as the denomina-
tor, to be 62.5%.
Waste and side effects. Vaccine wastage was monitored by
supervisors and project staff based on inventory of stock.
Wastage was documented to be 495 doses (< 0.5%).
No severe side effects were reported during or after the
campaign—19 vaccine recipients reported minor side effects.
Gastrointestinal disturbance was the most common side effect,
followed by dizziness, vomiting, or abdominal pain.
DISCUSSION
Despite the fact that newer oral cholera vaccines have been
demonstrated to be safe and effective in diverse settings, they
have not been deployed extensively in the setting of epidemic
cholera. Initial skepticism about the efficacy of such a strategy
was reduced by the understanding that herd immunity plays
an important role in cholera vaccination such that increasing
levels of vaccination coverage in a community contribute to
improved protection of not just the unvaccinated, but also
further protection of the vaccinated population.10,17,18 In part,
continued concern about cholera vaccination during epi-
demics has been about logistics and a fear of scarcity. Using
a cold chain-requiring product for large, rapid, and reactive
vaccination campaigns may seem less feasible during the
chaos of epidemic disease. This finding is particularly notable
given that such epidemics most often occur in regions with
fragile health systems.19 Concerns about scarcity of resources
may result in an attempt to pit one public health approach
against another rather than prompt an attempt to integrate
complementary approaches that might prevent disease, reduce
mortality, and strengthen the health system.
We aimed to demonstrate the acceptability and feasibility
of a reactive oral cholera vaccination campaign in the context
of the ongoing Haitian epidemic in synergy with continued
support of the other important components of cholera control,
such as case-finding, treatment, access to potable water, and
sanitation and hygiene education. We deemed the project suc-
cessful by virtue of the uptake and coverage rates described.
Some key aspects of our program contributed to success
including the staffing model and the engagement of commu-
nity leaders. The partnership between PIH and the MOH
occurred at all levels; MOH were key participants in strategic
decision-making and in supervision of the field activities.
Including a vaccination team member from the area being
vaccinated each day provided important local context to the
project and contributed to community trust in the activity.
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Engaging community leaders early in the process was impor-
tant because once their questions and concerns were
addressed, they naturally disseminated the information to
their constituents. Their support ensured that the campaign
was trusted and well understood. There had been some con-
cern cited before the campaign that the targeted approach
would lead to protests from communities not receiving vacci-
nation, but this did not occur. We believe this was due in part
to careful communications efforts.
Manufacturers of the OCV recommend that cold chain be
used to the point of vaccination. Cold chain storage capacity
in public or private health facilities in the region is limited,
largely relying on outdated propane back-up refrigerators and
lacking in cold boxes for community health workers. As part
of the project plan, under guidance from the National Vaccine
Program, we had purchased 10 solar powered refrigerators to
store the vaccine, but delays in their procurement and arrival
to Haiti meant that we had to rely on another source of
storage. As such, we were obliged to use a cold storage con-
tainer located inside a United Nations military base. Its loca-
tion meant that frequent entry and exit of the entire project
vaccination team was neither desirable nor logistically feasible,
Figure 2. A, Daily and cumulative first doses delivered in an oral cholera vaccination campaign in rural Haiti, 2012. B, Daily and cumulative
second doses delivered in an oral cholera vaccination campaign in rural Haiti, 2012.
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resulting in our need to use the dispatching warehouse for
smaller batches of vaccine for daily use. This necessity added
an additional transportation requirement and staffing that
could potentially have been avoided. If cold chain require-
ments were needed up until the day of vaccination only, a
significant savings in terms of equipment and logistics planning
could also have been made.
The six-week delay in starting the OCV campaign resulted
from a concern that the campaign was experimental and that
a research activity was being planned without proper ethical
consideration. In fact, using a pre-qualified vaccine with
documented efficacy and side effects in a demonstration pro-
ject was considered a public health service, not usually sub-
ject to ethics review. Those with the closest proximity to the
risk of being sickened by cholera had expressed no ethical
concerns. Thanks to swift communication between the ethics
committee, the project team and the MOH, the issue was
soon resolved, but the delay resulted in some important
issues including loss of trained staff to other commitments,
requiring another round of training for new staff; the onset
of the rainy season, causing some transportation difficulties
in this rural, flood-prone region; and the overlap with the
OPV campaign. This overlap required us to split our cam-
paign into two phases such that we ultimately returned to
each area four times, two doses for each phase. This split
had financial and logistics implications for the project.
Despite our concerns that it would be difficult to explain the
separation of children less than 10 years of age from others
in the campaign, this message was received without too
much complication by communities, as shown by high rates
of follow-up both children and adults.
We had initially anticipated vaccination only in the commu-
nity of Bocozel, but late in project planning realized that the
target population there had been overestimated. We there-
fore added the second community of Grand Saline in the
second phase of vaccination. Despite the shorter lead time to
introduce the campaign, there was still excellent uptake and
completion of second doses, leading us to believe that the
messages about the campaign were already being shared from
one community to the next by word of mouth. Because we
had not initially planned to intervene in this area, no census or
follow-up survey occurred in that region. The coverage rate
of 62.4% may be an underestimate given that the denominator
used for the calculation was from demographic data over three
years old. Regardless of the method used for calculation, the
overall coverage rates for both communities are within the
range that would be expected to provide herd immunity.
Because the project was intended specifically to inform
future practice on the use of OCV, we undertook data collec-
tion at a level more detailed than usually occurs during our
community vaccination campaigns and chose to capture data
electronically using handheld devices. We explored a number
of technology platforms before choosing one. Important con-
siderations were ease of use, durability, cost, and the limita-
tions of our catchment area, including the rural environment,
and lack of power and other infrastructure in the field. Scan-
ning barcodes pre-printed on vaccine cards (rather than relying
on manual entry) afforded our team swiftness and accuracy
throughout pre-registration during the census, as well as during
the vaccination phase. The technology platform used was
accessible and user-friendly. High-school educated staff were
able to quickly learn and familiarize themselves with the tablet
and data collection software. Nightly review of the data also
facilitated day-to-day changes in vaccination strategy that
helped the efficiency of the vaccine teams and likely contrib-
uted to the excellent follow up rates.
There were no major side effects reported with the use
of the vaccine, and this finding is consistent with previous
experience with this vaccine.20 The project highlighted the
fact that there is a weak formal Adverse Effects Following
Immunization system in Haiti and this should be reinforced
for all existing and future planned vaccination activities.
This was a public health intervention and research was not
a primary objective. There remain a number of operational
questions that would benefit from further study to facilitate
the use of OCV in future scenarios. These questions include
Table 1
Vaccination by location, age group and gender in an oral cholera vaccination campaign in rural Haiti, 2012
Population Bocozel, no. (%) Grand Saline, no. (%) Total, no. (%)
Community coverage 76.7–92.7%* 62.5%†
Received at least 1 dose 32,210 (70.9) 13,207 (29.1) 45,417
Sex
F 15,799 (49.0) 6,630 (50.2) 22,429 (49.4)
M 16,383 (50.9) 6,555 (49.6) 22,938 (50.5)
Age, years
1–4 3,630 (11.3) 1,268 (9.6) 4,898 (10.8)
5–9 3,887 (12.1) 1,792 (13.6) 5,679 (12.5)
10–17 5,744 (17.8) 2,505 (19.0) 8,249 (18.2)
³ 18 18,921 (58.7) 7,620 (57.7) 26,541 (58.4)
Completion rate
Received 2 doses 29,204 (90.7) 12,038 (91.1) 41,242 (90.8)
Sex
F 14,426 (91.3) 6,147 (92.7) 20,573 (91.7)
M 14,752 (90.0) 5,869 (89.5) 20,621 (89.9)
Age, years
1–4 3,400 (93.7) 1,188 (93.7) 4,588 (93.7)
5–9 3,665 (94.3) 1,697 (94.7) 5,362 (94.4)
10–17 5,217 (90.8) 2,268 (90.5) 7,485 (90.7)
³ 18 16,895 (89.3) 6,863 (90.1) 23,758 (89.5)
*Lower limit was calculated by census data, and upper limit was calculated by post-campaign coverage survey.
†Calculated using government demographic data.
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clarification on the need for maintaining cold chain until
the point of administration versus until the day of vaccina-
tion, and whether the interaction with OPV is a real or just
theoretical concern. A recent study of WC-rBS was reassuring
regarding the safety of that vaccine during pregnancy; how-
ever, further data are needed to clarify recommendation on
the use of OCVs in pregnant women.21 It is also important to
consider the role that dissensus played in the failure to rapidly
deploy an effective technology during the epidemic in Haiti.
OCV has now been studied retrospectively and prospectively
in epidemic cholera and this report adds to evidence of the
feasibility of OCV in such circumstances.10,22–25
In conclusion, vaccination with OCV was acceptable and
feasible in rural Haiti during an epidemic of cholera. There
were high rates of community coverage in an initial area with
intense pre-campaign communications and in a second com-
munity with a shorter pre-campaign communications. All
communities had excellent rates of completion of second dose
of the vaccine. Community engagement in the OCV campaign
was critical to success.
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